Large-scale testing (Phase 3)Study completedNCT01780935
What this trial is testing
Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 671